Relationship Between Systemic Lupus Activity Measurement (SLAM) Score and Mortality in Systemic Lupus Erytemathosus (SLE) Inpatients by Paramaiswari, Ayu et al.
The Journal of  Internal Medicine, Acta Interna, Volume 4, Number 1, June 2014: 15-22
15 
Relationship Between Systemic Lupus Activity 
Measurement (SLAM) Score and Mortality
in Systemic Lupus Erytemathosus (SLE)
Inpatients
Hubungan Antara Nilai Systemic Lupus Activity Measurement (SLAM)
dan Kematian pada Pasien Lupus Eritomatosus Sistemik (LES)
Ayu Paramaiswari,1 Nyoman Kertia,1 Deddy Wachid Achadiyono1
The Division of  Rheumatology, Department of  Internal Medicine, Faculty of  Medicine, 
Universitas Gadjah Mada/Dr. Sardjito General Hospital
ABSTRAK
Latar Belakang: Lupus Eritomatosus Sistemik (LES) adalah penyakit autoimun kronis yang berat dan mengancam 
jiwa. Kematian pada LES dapat disebabkan oleh aktivitas lupus atau sequel jangka panjang.  Nilai  SLAM adalah suatu 
alat yang dapat mengukur aktivitas penyakit pada pasien penderita lupus.
Tujuan: Menganalisa hubungan antara nilai Systemic Lupus Activity Measurement (SLAM) dan mortalitas pada 
penderita Lupus Eritomatosus Sistemik. 
Metode: Studi kohort retrospektif  dipakai untuk mencapai tujuan penelitian. Penderita Lupus rawat inap dipakai sebagai 
populasi penelitian. Rekam medis dipakai untuk mengumpulkan data penelitian selama periode 2006-2011. Variabel 
independen adalah nilai SLAM. Batasan nilai SLAM dibuat berdasarkan rata-rata nilai SLAM (nilai 16.7). Variabel 
dependen adalah mortalitas.
Hasil penelitian: Terdapat perbedaan  median survival antara nilai yang kurang dan lebih dari 16.7, yaitu masing-masing 
45 and 28 (p 0.034). Terdapat hubungan antara nilai SLAM (lebih dari 16.7) dan HR mortalitas sebesar 2.78 (95% 
CI 1.028-7.52). Terdapat perbedaan antara jumlah kriteria ACR yang ada, pneumonia, heart rate dengan nilai SLAM 
(nilai p masing-masing 0.001; 0.001; 0.002). Terdapat perbedaan insiden kematian antara nilai yang lebih dan kurang 
dari 16.7  yaitu masing-masing 0.35 dan 0.10. Terdapat hubungan antara nilai SLAM (lebih dari 16.7) dengan RR 
mortalitas sebesar 3.5 (95% CI). Mortalitas pada penderita LES rawat inap adalah sebesar 23%.
Kesimpulan: Terdapat hubungan antara nilai SLAM dengan mortalitas penderita lupus yang menjalani rawat inap.
Kata kunci: LES, SLAM, kematian
ABSTRACT
Background: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder that can be severe 
and life threatening. Mortality in SLE may due to lupus activity or long-term sequel. Systemic Lupus Activity 
Measurement (SLAM) score is a tool that can count lupus disease activity inpatients.  
Aims: To analyze the relationship between SLAM score and mortality in lupus inpatients.
Methods: Retrospective cohort study used for reaching objective of  the study. Lupus inpatients was used 
as research population. Medical record was used as study data collection over periods of  2006 until 2011. 
Independent variable was a SLAM score. The cut point of  SLAM score was made based on the mean of  
SLAM score (16.7 point score). Dependent variable was mortality.
Results: There were differences between number of  ACR criteria fi ndings, pneumonia, heart rate with 
SLAM score (p value 0.001; 0.001; 0.002 respectively).There was a difference of  median survival between 
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INTRODUCTION
SLE is a multisystem autoimmune disorder 
characterized by production of  several auto 
antibodies against many spectrums of  self-
antigen from nucleus, cytoplasm, and surface auto 
antigen in a predisposing specifi c genetics that can 
be severe and life threatening.1, 2 Mortality in SLE 
can be caused by disease activity (when major 
organ or organ system involved), complication 
of  treatment (especially infection), or long term 
sequel like in cardiovascular diseases.3 Even in 
general it has been accepted that high disease 
activity from time to time will increase risk of  
organ damage and mortality, only few studies that 
aimed to scale this association in detail. A cohort 
study done in University College Hospital (UCH) 
in 141 SLE patients showed that the average 
higher British Isles Lupus Assessment Group 
(BILAG) score associated with organ damage 
and mortality in the fi fth year. Other study in 158 
Norwegian lupus patients using  Systemic Lupus 
Erythematous Disease Activity Index (SLEDAI) 
as disease activity measurement predict that 
there was an increase  Hazard Ratio (HR) of  
organ damage  (SLE Damage Index (SDI) >3) 
in patients with higher SLEDAI score compared 
to those with lower SLEDAI score.4
Among several systems that can measure 
SLE disease activity, SLAM is a very good 
tool. SLAM or SLAM-R (revised) is one of  
several indices with proven strongest validity 
that has been used in many researches in many 
countries with a big scale. SLAM consists of  
measurement of  24 clinical manifestations, 
7 laboratory parameters to evaluate disease 
activity. Each point have value related to its 
degree of  severity, with total score indicating 
overall disease activity (higher score indicating 
more active disease). SLAM includes subjective 
complain reported by patients and exclude 
serology/immunology measurement.5, 6, 7
This study is aimed to analyze correlation 
between SLE disease activities measured by 
SLAM score with mortality in SLE inpatients. 
Below is the result of  study that measure 
correlation between SLE disease activity with 
mortality and factors that associate with SLE 
disease activity in Dr. Sardjito General Hospital 
Yogyakarta wards. 
METHODS
Study Population
Target population in this study was all 
medical records under ICD X code M 32.9 in 
Sardjito General Hospital. Reached population 
were medical records under ICD X code M 
32.9 on 2004-2011.
Study Design
This design used retrospective cohort 
study, by looking to medical records, and then 
divided into two conditions, died or allowed 
less and more than 16.7 point score, 45 and 28 respectively (p 0.034). There was a relationship between 
SLAM score (more than 16.7 point score) and mortality HR 2.78 (96% CI 1.01-7.53).There was a difference 
of  mortality incidence between more and less than 16.7 point score, 0.35 and 0.10 respectively. There was 
a relationship between SLAM score (more than 16.7 point score) and mortality RR 3.5 (95% CI). Mortality 
in lupus inpatients was 23%.
Conclusion: There was a relationship between SLAM score and mortality on lupus inpatients.
Keywords:  SLE,  SLAM,  Mortality
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Table 1. Baseline Characteristic Subject
Variable Result
Age, years
Age < 37 years, n (%)
Age > 37 years, n (%)
28 ± 9.8
84 (79.2)
22 (20.8)
Gender
Male, n (%)
Female, n (%)
10 (9.4)
96 (90.6)
Length of  education, years
<12 years, n (%)
> 12 years, n (%)
10.6± 2.7
93 (87.7%)
13 (12.3%)
Payment methods
Self  fi nance, n (%)
Insurance (Askes, Jamkesmas, 
Jamkesda, Gakin), n (%)
60 (56.6)
46 (43.4)
Outcome
Survive, n (%)
Dead, n (%)
82 (77.4)
24 (22.6)
Age at onset
< 40, n (%)
> 40, n (%)
25.75±  10.46
61(57.5)
45 (42.5)
Length of  illness, weeks
< 48 weeks, n (%)
> 48 weeks, n (%)
112.08± 174.58
64 (59.4)
43 (40.6)
Hb (g/dl) 8.8± 2.85
to go home (survivor). Data were taken from 
two groups, exposed and unexposed (control). 
Exposed group were subjects with high 
disease activity where as control group were 
subjects with low disease activity. Periods of  
study were 30 days. Inclusion criteria were 
medical records under ICD X code M32.9 
that met ACR criteria 1999 for diagnosis 
of  SLE, discharge from hospital due to die 
or allowed to go home (survivor), medical 
records can be accessed from medical record 
installation of  Sardjito General Hospital. 
Exclusion criteria were discharge from hospital 
by patient intention. Sampling method was 
consecutive sampling. Number of  sample is 
by total sampling. Independent variable was 
SLAM score, dependent variable was mortality. 
Confounding variable were age, age at disease 
onset, length of  illness, gender, treatment with 
oral methyl prednisolone.
RESULT
There were 280 lupus inpatients 
recorded between 2006 until 2011 under 
ICD 10 code M 32.9. Only 106 data met 
the inclusion and exclusion criteria. There 
were 96 (90.6%) female and 10 (9.4%) 
male. The mean age was 28 ± 9.8 years. 
The average of  illness was 112.08 ± 174.58 
weeks. The average length of  education 
was 10.6 ± 2.7 years. Mean age of  disease 
onset was 25.75±10.46 years. Co morbidities 
recorded were pneumonia (28.3%), Urinary 
Tract Infection (UTI) (21.7%). Methods 
Table 2. Baseline Characteristic of  
Subject
Variable Result
Mcv 74.59± 26.01
Mch 26.32 ± 12.41
Mchc 26.12 ±12.59
Albumin (g/dl) 2.2 ± 1.06
ALT
< 45, n (%)
>45, n (%)
69.22±  90.05
64  (60.4)
42 (39.6)
AST
<40, n (%)
>40, n (%)
44.09±  43.83
66 ( 62.3)
40  (37.7)
ACR criteria found
< 5 ACR, n (%)
>5 ACR, n (%)
60 (56.6)
46 (43.4)
Pneumonia, n (%)
No pneumonia, n (%)
30 (28.3)
76 (71.7)
UTI, n (%)
No UTI, n (%)
23 (21.7)
83 (78.3)
ANA
Negative, n (%)
Positive, n (%)
45 (42.5)
61 (57.5)
Thrombocyte 166858.37 ± 1.55
Leucocyte 8975.38
Anti-dsDNA
Negative, n (%)
Positive, n (%)
80 (75.5)
26 (24.5)
Use of   methyl prednisolone
<10mg/ day, n (%)
>10mg/day, n (%)
41 (38.7)
65 (61.3)
Heart rate
< 100 (x/minutes), n (%)
>100 (x/minutes), n (%)
58 (57.4)
48 (45.30)
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of  payment were by self-fi nance (56.6%) 
and insurance (Askes, Jamkesmas, Jamkesda, 
Gakin)  (43.4%). Lupus manifestations 
were hematology (95.3%), renal (76.4%), 
sororities (62.3%), arthritis (62.3%), positive 
ANA (57.5%), oral ulcer (56%), discoid 
rash (55.7%), neuropsychiatry (47.2%), 
photosensitive (34.6%), positive anti ds-
DNA (24.3%), and malar rash (18%).
There were proportion differences in 
number of  ACR criteria >5, pneumonia co 
morbidity, heart rate > 100/minute in group 
with SLAM score < mean value and SLAM 
Figure 1.  Univariate Analysis. 
Table 3. Proportion Difference for Each Variable According to Research Group
(Mean Value of  SLAM Score: 16,7).
Variable SLAM score <mean value SLAM score > mean value X2 P value
Number of  ACR criteria
< 5 (n)%
>5 (n)%
37 (72.5)
14 (27.5)
23 (41.8)
32 (58.2)
10.18 0.001
Co morbidities
Pneumonia (n)%
Non pneumonia (n)%
44 (86.3)
7 (13.7)
32 (58.2)
23 (41.8)
10.29 0.001
Heart Rate
< 100x/ minutes (n)%
>  100 x/ minutes (n)%
36 (70.6)
15 (29.4)
22 (40.0)
33 (69.0)
9.99 0.002
score > mean value 27.5; 58.2%; 86.3%; 58.2%; 
29.4%;69.0% respectively (p value: 0.001). 
There were no proportion differences in 
length of  education, age > 32 years, ALT > 45, 
AST > 40, use of  oral MP 10 mg/ day, length 
of  illness > 42 weeks, age of  disease onset > 40 
years, UTI co morbidity in group with SLAM 
score < mean value and SLAM score > mean 
value. The average length of  stay in hospital 
was 12. 5± 11.87 days. 
Figure 1 show that the longer length of  
stay in hospital, the smaller survival rate will 
be. Analysis was done in all subjects.
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Figure 2 shows that the longer length of  
stay, the higher mortality will be. Analysis was 
done in all subjects.
Figure 3 showed that that the longer 
length of  stay in hospital, the smaller survival 
rate will be, either in group more than mean 
value or less than mean value.
Figure 4 shows that the longer length of  
stay, the higher mortality will be either in group 
more than mean value or less than mean value. 
Figure 2. All mortalities according to time function
Figure 3. Patients survival according to each group
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Table 4. Median Survival Rate Were 
Difference in All Subjects According 
to High SLAM Score Groups and 
Low SLAM Score Groups. Variable in 
Categorical Scale
SLAM 
<mean
SLAM 
>mean X
2 P
Median surviva 
rate, days
45.00 28.00 4.47 0.034
Median survival rate subjects with SLAM 
score < mean value was 45 days and subjects 
with SLAM score >mean value was 28 days. 
There was a difference of  median survival rate 
between less and more than 16.7 point score, 
45 and 28 respectively (p 0.034). 
Table 5. The Association between SLAM 
Value and Mortality
Hazard Ratio 95% CI
SLAM >MEAN 
VALUE
2.78 1.028-7.52
In this bivariate model analysis, there 
was an increasing mortality risk in group with 
SLAM score > than mean value compared to 
group with SLAM score less than mean value 
as big as 2.78 HR (95% CI 1.02-7.52)
Table 6. Relative Risk of  Mortality 
between Groups 
Dead Survive Total
SLAM>mean 
value
19(34. 5%) 36 (65.5%) 55 (100%)
SLAM<mean 
value
  5 (9.8%) 46 (90. 2%) 51 (100%)
Mortality incidence in group with SLAM 
score < mean value was 0.35. Mortality 
incidence in group with SLAM score > mean 
value was 0.10. There was increasing mortality 
risk in groups with SLAM score > mean value 
compared to SLAM score < mean value as big 
as 3.5 RR (95% CI). Mortality rate in lupus 
inpatients was 0.23 (23%). 
Figure 4. Mortality according to each group
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Table 7. The Association of  Confounding 
Variable and Mortality in Categorial Scale 
Variable  Exp B P value
Gender 0.00 0.99
Age 0.74 0.25
Age of  disease onset 0.71 0.08
Oral methyl prednisolone 3.57 0.02
Length of  illness 1.14 0.90
There were no correlation between 
gender, age, age of  disease onset, length of  
illness with mortality, p value 0.99; 0.25; 0.08; 
0.90 respectively. There was a correlation 
between the use of  oral methyl prednisolone 
> 10 mg with mortality (p: 0.02). Group 
with the use of  oral methyl prednisolone > 
10mg had risk 3.57 times higher in mortality 
compared to group with the use of  oral  methyl 
prednisolone  < 10 mg. 
DISCUSSION 
Study conducted in Hospita l  de 
Especialidades Centro Medico National 
(HECMN), Siglo XXI, Instituto Mexicano 
del Seguro Social showed that between 2004-
2006 there were 41 lupus inpatients, mean 
age was 20±19. Mean length of  illness was 
21±9 month. Average number of  ACR criteria 
included was 6.5±1.5, 71% skin involvement, 
66% articular, 37% cardiopulmonary, 58% 
renal, 12 % neuropsychiatric, 73% hematology, 
95% immunology abnormality (92%, 85%, 
17%  positive ANA, Anti Ds DNA, Anti-
SM respectively).8 Calvo Alen et al found that 
major manifestations were hematology and 
musculoskeletal in both research groups.9 Renal 
and neurology manifestation signifi cantly more 
often found in Hispano-American (63.5 and 
67.3% respectively) than Spanish (33 and 20% 
respectively) (p=0.0025 and 0.0050).9
A longitudinal cohort study in 496 lupus 
patients found that as many as 98 (19.8%) were 
Hispanic, 93 (18.8%) Hispanic from Puerto 
Rico, 172 (34.7%) Afro-American, and 133 
(26.8%) were Caucasian. Most population were 
woman (90.5%), mean age was 35.9 years (SD 
12.2), mean length of  illness was 17.1 months 
(SD 16.1), and total length of  illness was 63. 
1 months (SD. 42.7).10 
This study consistent with Lopez et 
al (2012) showed that there was increase in 
mortality as much as 1.15 HR, P =0.007. 
That study used mean total BILAG score 
to measure disease activity. In group with 
the highest quartile of  mean total BILAG 
score had more increase risk of  mortality 
compared to lower mean total BILAG score.4 
Study by Apte et al (2008) showed that there 
was increase in mortality 1.08 HR, p= 0.008 
in group with SLAM-R score > mean value. 
This study used mean value of  SLAM-R for 
disease activity measurement. Subject with 
SLAM score more than mean value had 1.08 
x higher risk in mortality compared to group 
with lower mean SLAM –R score.10 Different 
result showed on study by Teh and Ling et al, 
where disease activity measured by SLEDAI 
score > 8 was not predictor of  mortality in 
SLE. In that study, infection, fl are at admission, 
SLE Damage Index, LOS, and flare were 
predictors of  mortality  with HR 9.33; 0.50; 
0.92; 0.4 respectively.11
CONCLUSION
There were differences between number 
of  ACR criteria fi ndings, pneumonia, heart rate 
with SLAM score (p value 0.001; 0.001; 0.002 
respectively). There was a difference of  median 
survival between less and more than 16.7 point 
Paramaiswari et al.
22 
score, 45 and 28 respectively (p 0.034). There 
was a relationship between SLAM score (more 
than 16.7 point score) and mortality HR 2.78 
(96% CI 1.01-7.53).
There was a difference of  mortality 
incidence between more and less than 16.7 
point score, 0.35 and 0.10 respectively. There was 
a relationship between SLAM score (more than 
16.7 point score) and mortality RR 3.5 (95% CI). 
Mortality in lupus inpatients was 23%.
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